Alliance E-News - March 2026
Spotlight on Scientific Annual Meetings
Alliance Investigators Present Research at 2026 SSO Meeting
Alliance researchers presented new research at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, held March 5-7 in Phoenix. SSO brings together surgical oncologists, researchers and trainees from around the world to discuss the latest advances in cancer care. It mobilizes a broad community of surgeons who strive to enhance patient care across all practice settings, recognizing that optimal patient care requires well-coordinated multidisciplinary teams where each participant serves a critical role.
Take a look.
Primary Presenters: Sepideh Gholami, MD, Northwell Health, and Eric Miller, MD, PhD, Ohio State University Comprehensive Cancer Center
Co-authors: Paul Romesser, MD, Memorial Sloan Kettering Cancer Center, Qian Shi, PhD, Mayo Clinic, Jesse Dixon, MS, Mayo Clinic, Sarah White, MD, MS, Medical College of Wisconsin, Christina Wu, MD, Mayo Clinic Arizona, Christopher Goulet, MD, Billings Clinic Cancer Center, Kyung-Wook Jee, PhD, Massachusetts General Hospital, Chadwick Wright, MD, PhD, University of Cincinnati, Rona Yaeger, MD, Memorial Sloan Kettering Cancer Center, Ardaman Shergill, MD, University of Chicago, Theodore Hong, MD, Beth Israel Deaconess Medical Center, Thomas George, MD, University of Florida, Eileen M. O'Reilly, MD, Memorial Sloan Kettering Cancer Center, Jeffrey Meyerhardt, MD, MPH, Dana-Farber Cancer Institute, Kathryn Hitchcock, MD, PhD, University of Florida
Colorectal cancer patients often experience long-term progression-free survival and overall survival following local treatment of isolated metastases, especially in the liver. However, the effectiveness of local ablative therapies, such as microwave ablation and stereotactic body radiation therapy, is uncertain. This trial aims to address this clinical challenge by evaluating the safety and efficacy of adding total ablative therapy to standard systemic treatment in patients with limited metastatic colorectal cancer. A022101/NRG-GI009 is a randomized phase II study set to enroll more than 150 patients with newly diagnosed metastatic colorectal cancer. Patients in Arm 1 will receive total ablative therapy, targeting all metastatic sites followed by standard systemic therapy. Patients in Arm 2 will continue with standard systemic therapy alone. Patient recruitment is ongoing.
